The 25 references in paper P. Laguta S., П. Лагута С. (2015) “ВЕНОЗНЫЕ ТРОМБОЗЫ: СОВРЕМЕННОЕ ЛЕЧЕНИЕ // CURRENT TREATMENT FOR VENOUS THROMBOSIS” / spz:neicon:aterotromboz:y:2015:i:2:p:7-16

1
Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler. Thromb. Vasc. Biol.,2008. 28(3): 370–372.
(check this in PDF content)
2
Tagalakis V et al. Incidence and mortality from venous thromboembolism in a real-world population: the QVTE Study Cohort. Am. J. Med., 2013. 126: 13–21.
(check this in PDF content)
3
Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation, 2003. 107 (23 Suppl 1): I9–I16.
(check this in PDF content)
4
Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA, 2003. 290: 1868–74.
(check this in PDF content)
5
Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep vein thrombosis or pulmonary embolism. Thromb. Haemost., 2002. 88: 407–14.
(check this in PDF content)
6
Kearon C. National history of venous thromboembolism. Circulation,2003. 107 (1): 22–130.
(check this in PDF content)
7
Kearon C, Akl EA, Comerota AJ. Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Guidelines (9thEdition). Chest, 2012. 141 (Suppl): 419–494.
(check this in PDF content)
8
Konstantinides SV. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur. Heart J., 2014. 35: 3033–80.
(check this in PDF content)
9
Baritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet,1960. 1: 1309–12.
(check this in PDF content)
10
Brandjes DPM, Heijboer H, Buller HR et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximalvein thrombosis. N. Engl. J. Med., 1992. 327: 1482–89.
(check this in PDF content)
11
Garsia DA, Baglin TP et al. Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Guidelines (9thEdition). Chest, 2012. 141 (Suppl): 24–43.
(check this in PDF content)
12
Dongen CJJ, van der Belt AGM, Prins MN. Fixeddose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev., 2004.
(check this in PDF content)
13
Couturand F, Julian JA, Kearon C. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis. Thromb. Haemost.,2001. 86: 980–4.
(check this in PDF content)
14
Boccalon H, Elias A, Chale JJ et al. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low molecular weight heparin: the Vascular Midi-Pyrenees study. Arch. Intern. Med., 2000. 160: 1769–73.
(check this in PDF content)
15
Middeldorp S. How I treat pregnancy-related venous thromboembolism. Blood, 2011. 118(20): 5394–5400.
(check this in PDF content)
16
Diepstraten J et al. Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using antiXa levels as endpoint. Eur J Clin Pharmacol,2015. 71: 25–34.
(check this in PDF content)
17
Buller HR, Davidson BL, Decousus H et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep vein thrombosis: a randomized trial. ANN. Intern. Med., 2004. 140: 867–73.
(check this in PDF content)
18
Buller HR, Davidson BL, Decousus H et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N. Engl. J. Med., 2003. 349: 1695–1702.
(check this in PDF content)
19
Gallus AS, Jackaman J, Tillett J et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet, 1986. 2: 1293–6.
(check this in PDF content)
20
Hull RD, Raskob GE, Rosenbloom D et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N. Engl. J. Med., 1990. 322: 1260–64.
(check this in PDF content)
21
Schulman S, Kearon C, Kakkar AK, Mismetti P et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med., 2009. 361: 2342–52.
(check this in PDF content)
22
Schulman S, Kakkar AK, Goldhaber SZ et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation,2014. 129: 764–772.
(check this in PDF content)
23
Prins MH, Lensin AW, Bauersachs R et al. Oral rivaroxaban for the treatment of symptomatic venous thromboembolism: a pooled analysis. Thromb. J., 2013. 11: 21.
(check this in PDF content)
24
Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of acute venous thromboembolism. N. Engl. J. Med., 2013. 369: 799–808.
(check this in PDF content)
25
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. The Hokusai-VTE Investigators. N. Engl. J. Med., 2013. 369: 1406–1415.
(check this in PDF content)